^
    over2years
    Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer. (PubMed, Front Genet)
    Among liquid biopsy specimens from the advanced NSCLC patients, pericardial effusion may be a better candidate for genomic profiling than plasma cfDNA, while it could serve as a supplement to PE-cfDNA in detecting actionable alterations. Therefore, pericardial effusion might provide a new alternative for selection of patients for better treatment management.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4)
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • EGFR exon 20 insertion • ALK fusion • EGFR L861Q • EGFR exon 19 deletion + EGFR T790M • KRAS G12 • HER-2 exon 20 mutation • EGFR exon 18 deletion • HER-2 exon 23 mutation • KRAS deletion
    over3years
    Efficacy of tyrosine kinase inhibitors against lung cancer with EGFR exon 18 deletion: Case report and pooled analysis. (PubMed, Cancer Treat Res Commun)
    Based on currently available data, afatinib was associated with a greater tumor response rate and a longer PFS than the first generation TKIs.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR exon 18 deletion
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)